![]() The clinical manifestation of COVID-19 varies from asymptomatic to a severe disease affecting the respiratory tract, that may evolve to ARDS, with patients admitted to the intensive care unit needing mechanical ventilation. SARS-CoV-2 is causing COVID-19, a pandemic burden with an unprecedented impact on healthcare systems worldwide. These data suggest that PLT-EVs might be an interesting biomarker deserving further investigations to test their predictive power. ROC analysis of the combined cohorts showed an AUC = 0.79 and an optimal cut-off value of 1472 EVs/μL, with 75% sensitivity and 74% specificity. PLT-EVs count were higher in Sars-Cov-2+ compared to Sars-Cov-2− patients or HC. Diagnostic performance of PLT-EVs was evaluated by receiver operating characteristic (ROC) curve. PLT-EVs were quantified by flow cytometry on two independent cohorts of Sars-CoV-2+ (n = 69), Sars-Cov-2− (n = 62) hospitalized patients, and healthy controls. The aim of this study was to evaluate the diagnostic performance of circulating platelets (PLT)-derived extracellular vesicles (EVs) as biomarkers for Sars-Cov-2 infection, by setting a rapid and reliable test on unmanipulated blood samples. Few biomarkers have been identified but, unfortunately, these are individually poorly specific, and novel biomarkers are needed to better predict patient outcome. Sars-Cov-2 infection causes fever and cough that may rapidly lead to acute respiratory distress syndrome (ARDS).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |